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Abstract
Background  and  objectives:  The  introduction  of  propofol  (2,6-diisopropylphenol)  as  a  sedative
agent has  transformed  the  area  of  sedation  for  endoscopic  procedures.  However,  a  major  draw-
back of  sedation  with  the  use  of  propofol  is  its  high  incidence  of  injection  pain.  The  most  widely
used technique  in  reducing  propofol  injection  pain  is  through  the  association  of  other  drugs.
The aim  of  this  study  was  to  evaluate  the  effect  of  remifentanil-propofol  combination  on  the
incidence  of  propofol  injection  pain  and  its  inﬂuence  on  the  total  dose  of  propofol  required  for
sedation in  upper  digestive  tract  endoscopy  (UDE)  diagnostic  tests.
Method:  One  hundred  and  ﬁve  patients  undergoing  upper  digestive  tract  endoscopy  were  eval-
uated and  randomly  divided  into  3  groups  of  35  patients  each.  The  Control  Group  received
propofol alone;  Study-group  1  received  remifentanil  at  a  ﬁxed  dose  of  0.2  mg/kg  combined
with propofol;  Study-group  2  received  remifentanil  at  a  ﬁxed  dose  of  0.3  mg/kg  combined  with
propofol.  The  incidence  of  propofol  injection  pain  and  the  total  dose  of  propofol  required  for
the test  were  evaluated.  The  sample  was  very  similar  regarding  age,  weight,  height,  sex,  and
physical  status.  Statistical  analysis  was  performed  according  to  the  nature  of  the  evaluated
data. Student’s  t-test  was  used  to  compare  the  mean  of  age,  weight,  height  (cm),  and  dose
(mg/kg) variables  between  groups.  The  2 test  was  used  to  compare  sex,  physical  status,  and
ween  groups.  The  signiﬁcance  level  was  ˛  <  0.05.
nt  statistical  difference  between  the  study  groups  and  the  control
eters  of  propofol  injection  pain  and  total  dose  of  propofol  (mg/kg)propofol injection  pain  bet
Results: There  was  signiﬁca
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used.  However,  there  were  no  statistical  differences  between  the  two  study  groups  for  these
parameters.
Conclusion:  We  conclude  that  the  use  of  remifentanil  at  doses  of  0.2  mg/kg  and  0.3  mg/kg  was
effective for  reducing  both  the  propofol  injection  pain  and  the  total  dose  of  propofol  used.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.
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Uso  do  remifentanil  para  reduc¸ão da  dor  à  injec¸ão de  propofol  e  a  dose  necessária  de
propofol  em  exames  de  endoscopia  digestória  alta  diagnóstica
Resumo
Justiﬁcativa  e  objetivos:  A  introduc¸ão  do  propofol  (2,6-di-isopropilfenol)  como  agente  sedativo
tem transformado  a  área  da  sedac¸ão  para  procedimentos  endoscópicos.  Entretanto,  um  grande
inconveniente  da  sedac¸ão  com  o  uso  do  propofol  é  sua  alta  incidência  de  dor  à  injec¸ão.  A  técnica
mais usada  na  reduc¸ão  da  dor  à  injec¸ão  do  propofol  tem  sido  a  associac¸ão  com  outros  fármacos.
O objetivo  deste  estudo  foi  avaliar  a  repercussão  da  associac¸ão  do  remifentanil  com  o  propofol
na incidência  de  dor  à  injec¸ão  de  propofol  e  a  inﬂuência  na  dose  total  de  propofol  necessária
para sedac¸ão  em  endoscopia  digestória  alta  (EDA)  diagnóstica.
Método:  Foram  avaliados  105  pacientes,  submetidos  à  EDA  diagnóstica  e  divididos  aleatoria-
mente em  três  grupos  de  35.  O  Grupo  Controle  foi  sedado  apenas  com  propofol.  O  Grupo  de
Estudo 1  foi  sedado  com  remifentanil  em  dose  ﬁxa  de  0,2  g/kg  associado  ao  propofol.  E  o
Grupo de  Estudo  2  foi  sedado  com  remifentanil  em  dose  ﬁxa  de  0,3  g/kg  associado  ao  propo-
fol. Foram  avaliadas  a  incidência  de  dor  à  injec¸ão  de  propofol  e  a  dose  de  propofol  necessária
para o  exame.  A  amostra  se  mostrou  bastante  similar  em  relac¸ão  às  variáveis  idade,  peso,
altura, sexo  e  estado  físico.  De  acordo  com  a  natureza  dos  dados  estudados,  procedeu-se  ao
tratamento  estatístico  julgado  adequado.  Usou-se  o  teste  t  para  comparac¸ão,  entre  os  grupos
analisados,  das  médias  das  variáveis  idade,  peso,  altura  (cm)  e  dose  (mg/kg).  Foi  usado  o  teste
2 para  comparac¸ão,  entre  os  grupos  analisados,  das  variáveis  sexo,  estado  físico  e  dor  à  injec¸ão
de propofol.  O  nível  de  signiﬁcância  adotado  foi    <  0,05.
Resultado:  Houve  diferenc¸a estatística  signiﬁcativa  entre  os  grupos  de  estudo  e  o  grupo  controle
tanto no  parâmetro  dor  à  injec¸ão  de  propofol  quanto  no  parâmetro  dose  de  propofol  usada
(mg/kg). Entretanto,  não  houve  diferenc¸as  estatísticas  entre  os  dois  grupos  de  estudo  para
esses parâmetros.
Conclusão:  O  uso  do  remifentanil  nas  doses  de  0,2  g/kg  e  de  0,3  g/kg  mostrou-se  efetivo
tanto sobre  o  parâmetro  reduc¸ão  da  dor  à  injec¸ão  de  propofol  quanto  sobre  o  parâmetro  dose
de propofol  usada.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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n  many  countries,  sedation  has  become  routine  in  patients
ndergoing  colonoscopy  and  diagnostic  upper  digestive  tract
ndoscopy  (UDE).1 According  to  a  survey  from  the  American
ollege  of  Gastroenterologists,  sedation  is  used  in  over  98%
f  colonoscopy  exams  and  UE  in  the  United  States.2 The  term
edation  is  used  for  depression  of  an  individual’s  level  of  con-
ciousness.  Sedation  is  used  to  promote  anxiolysis,  amnesia,
nd,  in  some  instances,  analgesia.3The  introduction  of  propofol  (2,6-diisopropylphenol)  as
 sedative  agent  has  transformed  the  area  of  sedation
or  endoscopic  procedures.3 Much  of  propofol’s  popular-
ty  between  physicians  and  patients  is  related  to  its
o
n
tharmacokinetic  and  pharmacodynamic  properties,  which
ives  the  drug  a  quick  start  and  end  of  its  effects  and  pro-
ides  the  patient  a  sense  of  well-being.3 In  many  respects,
ropofol  is  an  ideal  agent  for  short  procedures  in  outpa-
ients.  However,  because  of  its  pharmacological  proﬁle,  one
f  its  recommendations  is  to  be  used  only  by  professionals
rained  in  the  administration  of  general  anesthesia.4 A  major
rawback  of  sedation  using  propofol  is  its  high  incidence  of
njection  pain.5,6 The  presence  of  propofol  injection  pain
anges  from  28%7 to  90%8 of  cases.
9Macario  et  al. questioned  among  American  anesthesiol-
gists  which  anesthetic  clinical  outcomes  are  common  and
ecessary  to  avoid.  Propofol  injection  pain  during  anes-
hetic  induction  was  ranked  as  the  seventh  most  important
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TUse  of  remifentanil  to  reduce  propofol  injection  pain  and  th
among  33  clinical  outcomes,  when  taking  into  account
frequency  and  clinical  signiﬁcance  together.  Many  stud-
ies  have  been  conducted  seeking  to  minimize  or  resolve
this  problem.10 Even  after  changing  the  original  formula-
tion  of  propofol,  the  cremophor  thinner,  which  was  linked
to  anaphylactic  reaction,11 to  a  lipid  emulsion,  the  pain
remained.  This  shows  that  it  is  due  to  the  drug  itself,  not  the
formulac¸ão.12 That  is  to  say  that  the  use  of  lipid  emulsion
almost  abolished  the  pain  associated  with  diazepam  and  eto-
midate  injection.13--15 Optional  propofol  formulations  with
changes  in  the  composition  of  the  lipid  emulsion,  differ-
ent  fractions  of  medium-  and  long-chain  triglycerides,  and
use  of  different  preservatives,  such  as  ethylenediamine-
tetraacetic  acid  (EDTA)  and  sodium  metabisulﬁte,  did  not
eliminate  the  injection  pain.16 However,  it  has  been  sug-
gested  that  increased  lipid  solvent  content  may  reduce  the
concentration  of  free  propofol  in  the  aqueous  phase  and
its  contact  with  free  nerve  endings,  which  could  reduce
propofol  injection  pain  during.17--22 Recommendations  such
as  using  large-caliber  veins  help  reduce  propofol  injec-
tion  pain.  However,  the  most  widely  used  technique  to
reduce  propofol  injection  pain  has  been  the  combination
of  other  drugs  such  as  lidocaine,23--25 ephedrine,24 magne-
sium  sulfate,26 thiopental,25 ketamine,27 acetaminophen,28
and  tramadol,29 among  others.
Opioids  are  the  drugs  most  commonly  used  in  combina-
tion  with  propofol  for  anesthesia.  Its  use  in  the  reduction
of  propofol  injection  pain  is  widespread  and  has  proved  to
be  effective  in  most  clinical  studies,30,31 although  it  was
proved  ineffective  in  the  study  by  Basaranoglu  et  al.32 It  is
known  that  intravenous  anesthetics,  such  as  hypnotics,  opi-
oids,  and  benzodiazepines,  combine  synergistically  during
anesthesia.33 These  drugs  are  associated  in  order  to  poten-
tiate  the  effects  of  the  interaction  between  propofol  and
opioids34;  thus,  the  desired  effects  can  be  achieved  with
lower  doses  of  drugs.  In  very  short  outpatient  procedures,
such  as  endoscopic  examinations  or  lumbar  puncture  in  pedi-
atric  patients,35 the  association  of  remifentanil  and  propofol
enables  extremely  fast  recovery  with  short  duration  pharma-
codynamic  effects.
The  aim  of  this  study  was  to  evaluate  the  effects  of
remifentanil  associated  with  propofol  in  the  incidence  of
propofol  injection  pain  and,  concomitantly,  the  inﬂuence  of
the  remifentanil  association  on  propofol  dose  required  for
sedation  in  diagnostic  UDE.
Method
The  study  was  conducted  after  approval  by  the  Research
Ethics  Committee  of  the  institution,  and  all  patients  were
informed  about  the  project  and  signed  the  informed  con-
sent.
A  total  of  105  patients  of  both  genders,  physical  sta-
tus  ASA  I  or  II,  undergoing  diagnostic  UDE  was  selected.
Exclusion  criteria  were  patients  aged  under  18  and  over
65,  pregnant  women  with  a  history  of  allergy  to  any  com-
ponent  of  the  study  drugs,  in  whom  it  was  necessary,  in
addition  to  the  diagnostic  test,  any  kind  of  therapy  dur-
ing  the  procedure,  and  any  patient  with  physical  status
ASA  >  II.
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The  patients  were  randomly  divided  into  three  groups  by
rawing  lots:
Control  Group  (n  =  35),  received  sedation  with  propofol
alone  for  diagnostic  UDE.
Study  Group  1  (n  =  35),  received  sedation  with  remifen-
tanil  at  ﬁxed  dose  of  0.2  g/kg  combined  with  propofol
for  diagnostic  UDE.
Study  Group  2  (n  =  35),  receive  sedation  with  remifentanil
at  ﬁxed  dose  of  0.3  g/kg  combined  with  propofol  for  diag-
nostic  UDE.
Patients  who  met  the  inclusion  criteria  were  monitored
ith  cardioscopy,  pulse  oximetry,  and  noninvasive  blood
ressure,  using  the  multiparameter  Philips  C3  Monitor,  type
lasses  nasal  catheter  placement  with  O2 ﬂow  (3  L/min)
nd  peripheral  22G  venous  puncture  catheter  in  antecubital
egion  for  0.9%  isotonic  saline  and  sedatives  infusion.  The
atients  were  then  placed  in  the  left  lateral  position  for  the
xam.
Using  a  syringe,  10  mL  isotonic  0.9%  saline  at  a  rate
f  1  mL  every  3  s  was  administered  to  the  Control  Group;
emifentanil  0.2  g/kg  to  the  Study  Group  1;  and  remifen-
anil  0.3  g/kg  to  the  Study  Group  2.  Subsequently,  propofol
as  administered  using  a  20  mL  syringe  at  a  rate  of  1  mL
very  3  s.  During  propofol  injection,  the  patient  was  asked
f  he  felt  any  pain  in  the  arm  with  the  catheter  and  if
t  was  located  at  the  injection  site.  All  patients  were
sked  identically.  Propofol  was  injected  to  loss  of  conscious-
ess,  checked  by  the  lack  of  response  to  verbal  stimulation
nd  loss  of  ciliary  reﬂex  and  conﬁrmed  by  all  team
embers.  All  examinations  were  performed  by  the  same
ndoscopist,  and  the  time  of  the  patient’s  recovery  was
eriﬁed  by  spontaneous  eye  opening  in  response  to  verbal
timulation.
Data  on  age,  weight,  sex,  height,  physical  status,  pres-
nce  or  absence  of  propofol  injection  pain  and  propofol
ose  at  mg/kg  were  recorded  in  speciﬁc  worksheet  at  the
roposed  time  points.
According  to  the  nature  of  the  data  studied,  the  appro-
riate  statistical  analysis  was  performed.  We  used  the  t
est  to  compare  between  groups  the  mean  of  the  variables
ge,  weight,  height  (cm),  and  dose  (mg/kg).  The  2 test
as  used  to  compare  gender,  physical  status,  and  propofol
njection  pain  between  groups.  The  signiﬁcance  level  was
 <  0.05.
esults
he  groups  were  homogeneous  with  respect  to  age,  weight,
eight,  sex,  and  physical  status.  A  descriptive  summary  of
ach  group  is  shown  in  Tables  1--3.
The  incidence  of  propofol  injection  pain  in  Control  Group
as  present  in  40%  of  patients  and  signiﬁcantly  lower  in
he  study  groups  pre-medicated  with  doses  of  remifentanil
.2  g/kg  (14.28%)  and  remifentanil  0.3  g/kg  (14.28%).
here  was  no  statistical  difference  between  the  Study
roups  1  and  Study  Group  2  regarding  the  incidence  propofol
njection  pain  (Table  4  and  Figs.  1--3).
The  mean  dose  of  propofol  used  was  2.07  mg/kg  in  Con-
rol  Group,  with  a  range  from  0.93  to  3.17  mg/kg,  and  it  was
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Table  1  Comparison  of  mean  age,  weight,  and  height  (cm)
in the  analyzed  groups:  t  test.
Groups  n  Idade  p
Min--max  Mean  ±  SD
Study  1  35  18--60  36.17  ±  11.73  0.34
Study 2  35  20--52  33.89  ±  7.99
Study 1 35  18--60  36.17  ±  11.73  0.43
Control  35  20--60 34.14  ±  9.28
Study 2 35  20--52 33.89  ±  7.99 0.90
Control  35  20--60 34.14  ±  9.28
Groups  n  Weight  p
Min--max  Mean  ±  ±  SD
Study  1  35  48--98  69.20  ±  13.19  0.77
Study 2  35  50--94  70.09  ±  11.87
Study 1  35  48--98  69.20  ±  13.19  0.12
Control  35  50--110  74.00  ±  12.18
Study 2  35  50--94  70.09  ±  11.87  0.18
Control  35  50--110  74.00  ±  12.18
Groups  n  Height  (cm)  p
Min--max  Mean  ±  SD
Study  1  35  150--180  165.77  ±  7.01  0.75
Study 2  35  150--182  166.34  ±  7.88
Study 1  35  150--180  165.77  ±  7.01  0.34
Control  35  155--184  167.57  ±  8.51
Study 2  35  150--182  166.34  ±  7.88  0.53
Control  35  155--184  167.57  ±  8.51
n, number of patients; min--max, minimum and maximum val-
s
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Table  3  Comparison  of  physical  status  in  the  analyzed
groups:  2 test.
Groups  ASA  Total  p
1  2
Study  1  29  6  35  0.26
Study 2  24  11  35
Study 1  29  6  35  1.0
Control  30  5  35
Study 2  24  11  35  0.15
Control  30  5  35
p, p-value probability.
Table  4  Comparison  of  propofol  injection  pain  in  the  ana-
lyzed groups:  2 test.
Groups  Propofol  injection  pain Total  p
Yes  No
Study  1  5  30  35  0.73
Study 2  5  30  35
Study  1  5  30  35  0.03
Control 14  21  35
Study  2  5  30  35  0.03
Control 14  21  35
D
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use  of  autonomic  responses,  and  early  awakening.
Anesthetics  with  these  characteristics  have  a  higher  pre-
dictability  of  its  pharmacodynamic  effects,  which  gives  a
Controlues; SD, standard deviation; p, p-value probability.
igniﬁcantly  higher  than  that  required  in  the  study  groups.
he  mean  dose  of  propofol  in  the  premedicated  group
ith  remifentanil  0.2  g/kg  was  1.25  mg/kg,  with  a  range
rom  0.89  to  2.17  mg/kg.  And  the  average  dose  of  propo-
ol  in  the  group  premedicated  with  remifentanil  0.3  g/kg
as  1.19  mg/kg,  with  a  range  of  0.51--1.91  mg/kg.  There
as  no  statistical  difference  in  the  mean  mg/kg  dose  of
ropofol  used  between  the  two  study  groups  (Table  5  and
ig.  4).Table  2  Comparison  of  sex  in  the  analyzed  groups:  2 test.
Groups  Sex  Total  p
Male  Female
Study  1  10  25  35  0.78
Study 2  8  27  35
Study  1  10  25  35  0.61
Control  13  22  35
Study  2  8  27  35  0.30
Control  13  22  35
p, p-value probability.
F
Gp, p-value probability.
iscussion
or  diagnostic  UDE,  the  ideal  characteristics  of  the  drugs
ould  be  a  quick  connection  with  the  effect  site,  reduced
ccumulation  in  the  body,  and  rapid  elimination,  which
ould  promote  rapid  pharmacodynamic  effects,  such  as
arly  hypnosis,  deep  sedation,  rapid  and  efﬁcient  controlYes
No
igure  1  Frequency  of  propofol  injection  pain  in  Control
roup.
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Group 1.
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pFigure  3  Frequency  of  propofol  injection  pain  in  Study
Group 2.
greater  safety  margin  to  the  anesthesiologist  and  prevents,
for  example,  a  prolonged  awakening  or  late  respiratory
depression.
Propofol  is  a  safe  and  effective  drug  for  gastrointesti-
nal  endoscopic  procedures  and  is  associated  with  shorter
recovery  period  and  earlier  hospital  discharge,  higher  scores
Table  5  Comparison  of  mean  dose  (mg/kg)  in  the  analyzed
groups: t  test.
Groups  n  Dose  (mg/kg)  p
Min--max  Mean  ±  SD
Study  1  35  0.89--2.17  1.25  ±  0.29  0.48
Study 2  35  0.51--1.91  1.19  ±  0.32
Study 1  35  0.89--2.17  1.25  ±  0.29  <0.0001
Control  35  0.93--3.17  2.07  ±  0.53
Study 2  35  0.51--1.91  1.19  ±  0.32  <0.0001
Control  35  0.93--3.17  2.07  ±  0.53
n, number of patients; min--max, minimum and maximum val-
ues; SD, standard deviation; p, p-value probability.
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bnd Study  Groups.
f  post-anesthetic  recovery,  better  sedation  and  increased
atient  compliance  regarding  traditional  sedation,  without  a
ncrease  in  cardiopulmonary  complications.36 However,  it  is
 drug  that  has  a  high  rate  of  injection  pain,  especially  with
maller  caliber  veins,  such  as  the  back  of  hands.37 To  reduce
ropofol  injection  pain,  puncture  of  larger  caliber  veins,
uch  as  the  antecubital  region,  should  be  recommended  for
nduction  and  maintenance  of  anesthesia  techniques  based
n  the  use  of  this  drug.
In  our  study,  it  was  shown  that  even  with  the  puncture
f  larger  caliber  veins,  the  incidence  of  propofol  injection
ain  still  remained  very  high,  around  40%.
Although  the  pain  etiology  is  not  exactly  established,
ifferent  methods  and  different  drugs  have  been  used  to
educe  its  incidence  and  severity.24 The  combination  of
rugs  with  the  aim  to  reduce  propofol  injection  pain  is
n  effective  and  technically  easy  method  and  independent
f  the  punctured  vein  location.  Most  drugs  associated  with
ropofol  to  reduce  injection  pain  or  was  not  studied  or  do
ot  signiﬁcantly  reduce  the  propofol  dose  required  for  induc-
ion  of  anesthesia.29,38 In  some  studies,  the  use  of  lidocaine
ombined  with  propofol  decreased  the  anesthetic  potency
f  propofol.39,40
Opioids  are  drugs  used  in  association  with  propofol  for
eneral  anesthesia  and  sedation.  An  important  reason  for
his  choice  in  the  present  study  is  that  opioids  are  syner-
istically  combined  with  propofol  and  effectively  reduce
ts  total  dose  during  anesthesia.  Fentanyl  and  alfentanil,
lthough  widely  used  in  anesthesia,  have  the  disadvantage
f  extending  its  clinical  to  the  postoperative  period,  par-
icularly  in  short  procedures.  A  reasonable  goal  would  be
o  reduce  propofol  injection  pain  without  the  appearance
f  other  adverse  effects,  such  as  delayed  recovery  from
nesthesia.
The  choice  of  remifentanil  was  based  on  its  rapid  onset
nd  offset  of  action,  which  decreases  the  incidence  of
esidual  side  effects.  However,  due  to  the  pharmacody-
amic  characteristics,  during  general  anesthesia  it  should
e  administered  as  a  continuous  infusion.  The  use  of  bolus
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ose  of  emifentanil  without  an  infusion  is  suitable  only  for
linical  procedures  that  require  intense  analgesia,  such  as
n  diagnostic  and  therapeutic  procedures  performed  out-
ide  the  operating  room  and  lasting  only  a  few  minutes.41
t  requires  less  preparation  time  of  anesthesia,  has  a  lower
ost  because  it  does  not  require  infusion  pumps  and  spe-
iﬁc  infusers.  In  2004,  Egan  et  al.  used  remifentanil  at  dose
olus  of  up  to  200  g,  which  showed  more  signiﬁcant  venti-
atory  effects  in  the  elderly  than  in  young  patients.41 These
ffects  were  short-lived  and  easily  managed  only  with  verbal
timulation  and  oxygen  addition  (2  L/min).  The  interaction
odel  and  ventilatory  involvement  proposed  by  La  Pierre
t  al.42 in  2012,  suggests  the  occurrence  of  greater  airway
bstruction  with  higher  concentrations  of  propofol  and  an
ntolerable  ventilatory  depression  with  high  concentrations
f  remifentanil.  The  same  author  also  proposes  a  signiﬁcant
ynergism  between  both  drugs.  This  indicates  that  lower
oses  of  each  are  required  to  achieve  the  same  effect.  The
esults  found  by  Hayes  et  al.,  in  2008,  indicate  that  in  the
ropofol-remifentanil  combination,  the  option  of  increas-
ng  the  remifentanil  dose  (1.5  g/kg)  and  decreasing  the
ropofol  dose  (2  mg/kg)  increased  the  duration  of  apnea
nd  reduced  the  recovery  time;  with  reduced  remifentanil
ose  (0.5  g/kg)  and  increased  propofol  dose  (4  mg/kg),
he  time  of  apnea  was  reduced  and  the  recovery  period
ncreased.35
The  use  of  pre-injection  bolus  doses  of  remifentanil  (0.2
nd  0.3  g/kg)  considered  low  compared  to  doses  previously
tudied30,32,35,41 is  justiﬁed  because  it  is  a  diagnostic  test
f  short  duration,  in  which  there  is  a  restriction  regarding
irway  management,  with  the  greatest  stimulus  during  the
evice  introduction,  the  peak  time  of  the  opioid  effect
hat,  according  to  Egan  et  al.,  2004,  occurred  2.5  min  after
njection.41 The  option  for  a  lower  dose  of  remifentanil
as  similar  to  that  suggested  by  Drover  et  al.,43 in  2004,
ecause  in  their  study  during  esophagogastroduodenoscopy
n  children,  lower  doses  minimized  episodes  of  oxygen
esaturation.  Increasing  the  dose  of  remifentanil  does  not
iminish  the  need  for  propofol  and  increases  the  risk  of  side
ffects  related  to  opioid.  Jeong  et  al.,44 in  2011,  showed
hat  a  dose  of  0.3  g/kg  was  effective  in  reducing  propo-
ol  injection  pain  even  with  the  use  of  the  dorsal  hand
eins  when  mixed  with  lidocaine;  however,  doses  of  0.5  and
.0  g/kg  were  more  effective.
Because  both  drugs  are  potent  depressant  of  ventilation
nd  based  on  the  principle  of  an  asymmetric  interaction
urve  between  the  drugs,  as  the  one  proposed  by  Fidler
t  al.,45 in  2006,  and  on  the  results  previously  found  by
ayes  et  al.,35 in  2008,  we  decided  in  this  study  to  use  a
ow  dose  of  remifentanil  and  assess  the  pharmacodynamic
nteraction  with  propofol  during  endoscopic  examinations.
nother  reason  for  choosing  these  doses  is  due  to  the  fact
hat  large  veins  of  the  antecubital  region  were  chosen  for
enous  access,  which  would  be  a  reduction  factor  of  propofol
njection  pain.
In  our  study,  as  in  many  others,46--50 it  is  shown  that
emifentanil  is  effective  in  reducing  propofol  injection  pain;
owever,  our  study  also  quantiﬁes  the  effect  of  two  doses
f  remifentanil  over  the  propofol  dose  required  to  achieve
 pharmacodynamic  effect  during  the  proposed  procedure.
At  doses  of  0.2  and  0.3  g/kg,  remifentanil  did  not  cause
edative  effect  that  could  alter  the  patient’s  perception  andG.N.  Uliana  et  al.
is  responsiveness  to  the  incidence  of  propofol  injection
ain.
Previous  studies  that  used  remifentanil  to  reduce  propo-
ol  injection  pain  have  methodological  differences  from
he  present  study.  Roehm  et  al.,46 in  2003,  collected  data
rom  patients  pretreated  with  midazolam,  using  venous
atheter  on  the  dorsum  of  the  hand  and  continuous  infusion
f  remifentanil.  Batra  et  al.,51 in  2004,  used  bolus  doses,
ut  with  venipuncture  in  the  back  of  the  hand  of  pediatric
atients,  in  addition  to  using  behavioral  parameters  for  mea-
urement  of  pain,  such  as  presence  of  grimace,  cry,  and  hand
emoval,  and  not  by  patient’s  objective  response.  Although
ropofol  the  time  of  balance  is  greater  than  the  remifen-
anil,  remifentanil  was  given  ﬁrst  because  one  of  the  study’s
bjectives  was  precisely  to  assess  the  interference  in  the
ropofol  dose  required  for  the  exam.
The  objectives  were  effectively  proven.  In addition  to
 signiﬁcant  reduction  in  propofol  injection  pain,  we  also
ound  a  signiﬁcant  reduction  in  the  propofol  dose  required
or  diagnostic  UDE.
The  difference  in  results  compared  with  previous  studies
ay  be  due  to  non-use  of  premedication,  different  injec-
ion  rate,  different  age  population  sample,  choice  of  larger
aliber  veins  of  the  antecubital  region,  and  pre-injection  of
emifentanil  in  different  doses  to  previous  studies.
In  this  study,  the  assessment  of  sedation  with  propofol  in
ombination  or  not  with  remifentanil  in  patients  undergoing
iagnostic  UDE  allowed  the  following  conclusions:
Pretreatment  with  remifentanil  signiﬁcantly  reduced
propofol  injection  pain.
Pretreatment  with  remifentanil  signiﬁcantly  reduced  the
propofol  dose  required  for  sedation.
There  was  no  statistically  signiﬁcant  difference  between
the  groups  receiving  pretreatment  with  remifentanil  at
doses  of  0.2  g/kg  and  0.3  g/kg  regarding  propofol  injec-
tion  pain  and  interference  in  the  used  dose  of  propofol.
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